Loading...
Bleximenib in combination with intensive chemotherapy: a phase 1b study in newly diagnosed acute myeloid leukemia with KMT2A or NPM1 alterations
Dohner, H. Schuh, A. Recher, C. O'Nions, J. Aldoss, I. Alfonso-Pierola, A. Allred, A. Alonso-Dominguez, J. M. Barreyro, L. Bories, P.
Dohner, H.
Schuh, A.
Recher, C.
O'Nions, J.
Aldoss, I.
Alfonso-Pierola, A.
Allred, A.
Alonso-Dominguez, J. M.
Barreyro, L.
Bories, P.
Abstract
Authors
Dohner, H.
Schuh, A.
Recher, C.
O'Nions, J.
Aldoss, I.
Alfonso-Pierola, A.
Allred, A.
Alonso-Dominguez, J. M.
Barreyro, L.
Bories, P.
Daskalakis, N.
Della Porta, M.
D'Souza, A.
Dugan, J.
Esteve, J.
Fathi, A.
Ferrante, L.
Gaj, S.
Garciaz, S.
Garrido, A.
Salamero, O.
Guttke, C. D.
Gyan, E.
Hiebert, B.
Jabbour, E.
Jentzsch, M.
Kantarjian, H.
Konopleva, M.
Kronke, J.
Hütter-Kronke, M. L.
Loefgren, C.
Lomas, O.
Mancini, V.
Mantzaris, I.
Morillo, D.
Packman, K.
Papayannidis, C.
Philippar, U.
Platzbecker, U.
Paniagua, S. G.
Sackey, N.
Sauer, T.
Searle, E.
Shastri, P. N.
Trancucci, D.
Tovar, N.
Vallet, N.
Vaughan, L.
Vyas, P.
Wei, A.
Rollig, C.
Schuh, A.
Recher, C.
O'Nions, J.
Aldoss, I.
Alfonso-Pierola, A.
Allred, A.
Alonso-Dominguez, J. M.
Barreyro, L.
Bories, P.
Daskalakis, N.
Della Porta, M.
D'Souza, A.
Dugan, J.
Esteve, J.
Fathi, A.
Ferrante, L.
Gaj, S.
Garciaz, S.
Garrido, A.
Salamero, O.
Guttke, C. D.
Gyan, E.
Hiebert, B.
Jabbour, E.
Jentzsch, M.
Kantarjian, H.
Konopleva, M.
Kronke, J.
Hütter-Kronke, M. L.
Loefgren, C.
Lomas, O.
Mancini, V.
Mantzaris, I.
Morillo, D.
Packman, K.
Papayannidis, C.
Philippar, U.
Platzbecker, U.
Paniagua, S. G.
Sackey, N.
Sauer, T.
Searle, E.
Shastri, P. N.
Trancucci, D.
Tovar, N.
Vallet, N.
Vaughan, L.
Vyas, P.
Wei, A.
Rollig, C.
Description
Date
2025
Publisher
Collections
Files
Loading...
Found from Unpaywall
Adobe PDF, 179.73 KB
Keywords
Type
Article
Citation
Dohner H, Schuh A, Recher C, O'Nions J, Aldoss I, Alfonso-Pierola A, et al. Bleximenib in combination with intensive chemotherapy: a phase 1b study in newly diagnosed acute myeloid leukemia with KMT2A or NPM1 alterations. Blood. 2025 NOV 3;146:5199-200.